Clinical Trial Update: SAP Depleter Dose Escalation Study in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of a SAP depleter in healthy volunteers; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• SAP Depleter

Snippet

Sponsor: GlaxoSmithKline | Conditions: Amyloidosis | Phase 1 | Status: COMPLETED